Get started
Author

Alba Cabirta

Observed names: A. Cabirta, A. Cabirta‐Touzon, Alba Cabirta Touzon, Alba Cabirta Touzón, Alba Cabirta-Touzón, Cabirta, Alba
Observed institutions: Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Hospital Universitario Fundación Jiménez Díaz, Hospital Universitario Infanta Leonor, Vall d'Hebron Institute of Oncology, Instituto de Investigación Sanitaria Fundación Jiménez Díaz
ORCID: 0000-0001-7198-8894
Observed ORCID: 0000-0001-7198-8894
OpenAlex ID: A5042982201
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
2021 · Livio Pagano, Jon Salmanton-García, et al. · Journal of Hematology & Oncology · 316
PDF
Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
2020 · David J. Pinato, Alberto Zambelli, et al. · Cancer Discovery · 179
PDF
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
2021 · Alessandro Busca, Jon Salmanton-García, et al. · Blood Advances · 78
Outcome of infection with omicron SARS‐CoV ‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
2022 · Ola Blennow, Jon Salmanton‐García, et al. · American Journal of Hematology · 74
PDF
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
2021 · Moraima Jiménez, Elisa Roldán, et al. · Blood Advances · 61
PDF
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
2022 · Francesco Marchesi, Jon Salmanton-García, et al. · Haematologica · 50
PDF
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
2023 · Alessandro Busca, Jon Salmanton-García, et al. · Frontiers in Immunology · 38
PDF
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
2024 · Jon Salmanton-García, Francesco Marchesi, et al. · EClinicalMedicine · 35
PDF
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
2023 · Jon Salmanton-García, Francesco Marchesi, et al. · EClinicalMedicine · 34
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial
2025 · Ali T Taher, Ali T Taher, et al. · The Lancet · 30
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
2023 · Jaap A. van Doesum, Jon Salmanton-García, et al. · Blood Advances · 27
PDF
Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
2023 · Giuseppe Rossi, Jon Salmanton-García, et al. · International Journal of Infectious Diseases · 19
PDF
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
2022 · Maria Stefania Infante, Jon Salmanton-García, et al. · Frontiers in Oncology · 19
PDF
Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
2023 · Pellegrino Musto, Jon Salmanton‐García, et al. · Hematological Oncology · 16
PDF
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
2024 · Tobias Lahmer, Jon Salmanton-García, et al. · Infection · 10
From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia
2023 · Pau Abrisqueta, Ferran Nadeu, et al. · Cancer Treatment Reviews · 9
PDF
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry
2023 · Monia Marchetti, Jon Salmanton-García, et al. · Therapeutic Advances in Hematology · 9
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
2022 · Chiara Cattaneo, Jon Salmanton-García, et al. · Cancers · 9
PDF
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry
2024 · Tommaso Francesco Aiello, Jon Salmanton-Garcia, et al. · Haematologica · 7
PDF
Neurotoxicity‐associated sinus bradycardia after chimeric antigen receptor T‐cell therapy
2022 · Eva Catalá, Gloria Iacoboni, et al. · Hematological Oncology · 6
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective
2021 · Gehan Soosaipillai, Anjui Wu, et al. · Therapeutic Advances in Medical Oncology · 6
Abstract CT174: A phase 1 study of JBH492, an anti C-C chemokine receptor 7 antibody-drug conjugate (anti-CCR7 ADC), assessing safety and efficacy in lymphoid malignancies
2024 · Pau Abrisqueta, Reinhard Marks, et al. · Cancer Research · 5
Real-World Data with the Use of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
2020 · M Moraima Jimenez, Sabela Bobillo, et al. · Blood · 4
Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
2026 · Maria Domenica Cappellini, Sujit Sheth, et al. · The Lancet · 3
Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia
2025 · Daniel Medina-Gil, Laura Palomo, et al. · Haematologica · 3
Works count: 70
Citation count: 1,087
H-index: 14
I10-index: 16
Year
Topic
Type